Lucid Diagnostics Inc. Common Stock (LUCD) is a publicly traded Healthcare sector company. As of May 21, 2026, LUCD trades at $1.00 with a market cap of $182.19M and a P/E ratio of -1.46. LUCD moved +5.60% today. Year to date, LUCD is -11.50%; over the trailing twelve months it is -23.08%. Its 52-week range spans $0.75 to $1.80. Analyst consensus is strong buy with an average price target of $3.90. Rallies surfaces LUCD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Lucid Diagnostics Posts $1.3M in Q1 EsoGuard Revenue, Secures $17M Offering: Lucid Diagnostics recorded $1.3M in Q1 2026 EsoGuard revenue, processing 3,177 tests. It raised $17M in a public offering to end Q1 with $45M pro forma cash and runway into 2027, and upcoming clinical guidelines will endorse EsoGuard and EsoCheck as the only non-endoscopic tests with high certainty.
| Metric | Value |
|---|---|
| Price | $1.00 |
| Market Cap | $182.19M |
| P/E Ratio | -1.46 |
| EPS | $-0.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.80 |
| 52-Week Low | $0.75 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.71M |
| Net Income | $-58.01M |
| Gross Margin | -41.73% |
5 analysts cover LUCD: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.90.